Literature DB >> 19413694

Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model.

Q-F Sun1, J-G Ding, D-Z Xu, Y-P Chen, L Hong, Z-Y Ye, M-H Zheng, R-Q Fu, J-G Wu, Q-W Du, W Chen, X-F Wang, J-F Sheng.   

Abstract

The objective of this study was to determine the predictive value of the model for end-stage liver disease (MELD) scoring system in patients with acute-on-chronic hepatitis B liver failure (ACLF-HBV), and to establish a new model for predicting the prognosis of ACLF-HBV. A total of 204 adult patients with ACLF-HBV were retrospectively recruited between July 1, 2002 and December 31, 2004. The MELD scores were calculated according to the widely accepted formula. The 3-month mortality was calculated. The validity of the MELD model was determined by means of the concordance (c) statistic. Clinical data and biochemical values were included in the multivariate logistic regression analysis based on which the regression model for predicting prognosis was established. The receiver-operating characteristic curves were drawn for the MELD scoring system and the new regression model and the areas under the curves (AUC) were compared by the z-test. The 3-month mortality rate was 57.8%. The mean MELD score for the patients who died was significantly greater than those who survived beyond 3 months (28.7 vs 22.4, P = 0.003). The concordance (c) statistic (equivalent to the AUC) for the MELD scoring system predicting 3-month mortality was 0.709 (SE = 0.036, P < 0.001, 95% confidence interval 0.638-0.780). The independent factors predicting prognosis were hepatorenal syndrome (P < 0.001), liver cirrhosis (P = 0.009), HBeAg (P = 0.013), albumin (P = 0.028) and prothrombin activity (P = 0.011) as identified in multivariate logistic regression analysis. The regression model that was constructed by the logistic regression analysis produced a greater prognostic value (c = 0.891) than the MELD scoring system (z = 4.333, P < 0.001). The MELD scoring system is a promising and useful predictor for 3-month mortality of ACLF-HBV patients. Hepatorenal syndrome, liver cirrhosis, HBeAg, albumin and prothrombin activity are independent factors affecting the 3-month mortality. The newly established logistic regression model appears to be superior to the MELD scoring system in predicting 3-month mortality in patients with ACLF-HBV.

Entities:  

Mesh:

Year:  2009        PMID: 19413694     DOI: 10.1111/j.1365-2893.2008.01046.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  36 in total

1.  Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure.

Authors:  Li-Yuan Wang; Qing-Hua Meng; Zhi-Qiang Zou; Yu-Chen Fan; Jie Han; Zhao-Xia Qi; Jian Ge; Ai-Ling Xu; Si-Kui Wang; Kai Wang
Journal:  Dig Dis Sci       Date:  2011-10-08       Impact factor: 3.199

2.  Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B.

Authors:  Fang-Yuan Gao; Yao Liu; Xiao-Shu Li; Xie-Qiong Ye; Le Sun; Ming-Fan Geng; Rui Wang; Hui-Min Liu; Xiao-Bing Zhou; Li-Li Gu; Yan-Min Liu; Gang Wan; Xian-Bo Wang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

3.  Prognosis of acute-on-chronic liver failure patients treated with artificial liver support system.

Authors:  Pi-Qi Zhou; Shao-Ping Zheng; Min Yu; Sheng-Song He; Zhi-Hong Weng
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

4.  Changes in circulating Foxp3(+) regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure.

Authors:  Xue-Song Liang; Cheng-Zhong Li; Yin Zhou; Wei Yin; Ya-Yun Liu; Wen-Han Fan
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014.

Authors:  Shiv Kumar Sarin; Chandan Kumar Kedarisetty; Zaigham Abbas; Deepak Amarapurkar; Chhagan Bihari; Albert C Chan; Yogesh Kumar Chawla; A Kadir Dokmeci; Hitendra Garg; Hasmik Ghazinyan; Saeed Hamid; Dong Joon Kim; Piyawat Komolmit; Suman Lata; Guan Huei Lee; Laurentius A Lesmana; Mamun Mahtab; Rakhi Maiwall; Richard Moreau; Qin Ning; Viniyendra Pamecha; Diana Alcantara Payawal; Archana Rastogi; Salimur Rahman; Mohamed Rela; Anoop Saraya; Didier Samuel; Vivek Saraswat; Samir Shah; Gamal Shiha; Brajesh Chander Sharma; Manoj Kumar Sharma; Kapil Sharma; Amna Subhan Butt; Soek Siam Tan; Chitranshu Vashishtha; Zeeshan Ahmed Wani; Man-Fung Yuen; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2014-09-26       Impact factor: 6.047

6.  A Novel prognostic scoring system to predict 3-month mortality risk in patients with acute-on-chronic liver failure in hepatitis B: a retrospective cohort study.

Authors:  Yu-Bao Zheng; Shi-Bin Xie; Dong-Ying Xie; Liang Peng; Zi-Ying Lei; Hong Deng; Bin-Liang Lin; Chao-Shuang Lin; Zhi-Xin Zhao; Wei-Min Ke; Zhi-Liang Gao
Journal:  Hepatol Int       Date:  2012-01-29       Impact factor: 6.047

Review 7.  Acute on Chronic Liver Failure-What is in a 'Definition'?

Authors:  Anil C Anand; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2016-09-01

Review 8.  Criteria for liver transplantation in ACLF and outcome.

Authors:  Albert Chi Yan Chan; Sheung Tat Fan
Journal:  Hepatol Int       Date:  2014-11-05       Impact factor: 6.047

9.  What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

Authors:  Ying Yan; Li Mai; Yu-Bao Zheng; Shao-Quan Zhang; Wen-Xiong Xu; Zhi-Liang Gao; Wei-Min Ke
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

10.  Predictors of the outcomes of acute-on-chronic hepatitis B liver failure.

Authors:  Hsiu-Lung Fan; Po-Sheng Yang; Hui-Wei Chen; Teng-Wei Chen; De-Chuan Chan; Chi-Hong Chu; Jyh-Cherng Yu; Shih-Ming Kuo; Chung-Bao Hsieh
Journal:  World J Gastroenterol       Date:  2012-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.